The first phase of a study, conducted to test the effectiveness of a new treatment against two aggressive types of thyroid cancer, revealed a long -term response to the new treatment that showed the level of safety safety.
The new treatment called “AIC 100” (AIC100) depends on the modified T cells “CAR”, which are genetically adjusted immune cells to attack cancer cells more accurately and effectively.
The experiment was conducted by researchers at the MD Anderson Cancer Center of the University of Texas, and these results were presented at the annual meeting of the American Cancer Research Association that was held last April, and was written by the Yurrick Arart website.
Treatment has shown positive responses in patients with two types of advanced thyroid cancer, “Anaplastic Thyroid Cancer” and “non -differented thyroid Cancer”. These two types of cancer are characterized by their beans, and they have limited therapeutic options, and this makes the new treatment a promising step towards improving the results of patients.
The experiment included 24 adult patients with advanced thyroid cancer, divided into different groups according to the dose levels. Before receiving treatment, some immune cells were destroyed to allow modified T -cells to work more effectively.
And 15 patients received experimental “AIC 100”, and they were divided into groups treated with 3 different levels of intravenous doses to determine the most effective and secure dose, the first dose was a very low dose, and the patients were not responded to. The second and third doses were higher and patients responded better.
No serious or toxic side effects were recorded that limit the lifting of the dose in the early stages of the experiment, and the third dose was the most effective and safe. Accordingly, a fourth dose was tested, but it was retracted after two patients were injured by pneumonia, and this prompted the researchers to return to the third dose and adopt it as the best option for the stages coming from studies.